ATCC 2023 Holiday Shipping Schedule: We will be closed from December 22nd to January 1st. To ensure timely delivery, please submit orders in accordance with the following: Domestic orders no later than December 15th for shipment by December 20th 2023; International orders no later than December 12th for shipment by the first week of January 2024. We will resume our normal shipping schedule on January 2nd, 2024. Thank you for your cooperation. 

  • Quick Order
  • Careers
  • Support

A Virus-Like Particle (VLP) Vaccine Displaying Zika Envelope (E) Protein CD Loop Antigen Elicits Protective and Specific Immune Response in a Murine Model

Purple tendrils and red spheres of the Zika virus.

ASM Microbe 2019

San Francisco, California, United States

June 20, 2019


Zika virus (ZIKV) is a mosquito-borne flavivirus associated with Congenital Zika Syndrome (CZS), which comprises a wide range of congenital abnormalities in fetuses and infants infected with ZIKV before birth. In a small number of patients, ZIKV infection is strongly associated with the neurological autoimmune disorder Gullian Barré Syndrome (GBS). To date, no vaccines or antiviral strategies are licensed for Zika Virus. Our aim is the development of a novel Zika vaccine candidate safe from antibody-dependent enhancement (ADE).

Download the poster to explore the development of a novel Zika vaccine candidate.


Watch the poster presentation